Nektar Therapeutics (NKTR) stock news · rev $55.2M
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
This NKTR news page leads with what Nektar Therapeutics filed — not a scraped headline mill.
No cached 8-K sentence for NKTR yet. We will not pad this page with generic market recap.
Latest reported NKTR revenue for 2025-12-31 was $55.2M. Net income was -$164.1M. Revenue was down 43.9% from 2024-12-31 to 2025-12-31. NKTR currently screens at market cap $307.2M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the NKTR stock page; for the tape open the quote page.
NKTR stock news FAQ
What are NKTR's latest revenue and net income?
Latest cached Nektar Therapeutics (NKTR) revenue for Dec 31, 2025 was $55.2M. Net income was -$164.1M. Statements: https://lician.com/financials/nktr
How did NKTR revenue change from the prior cached period?
Cached Nektar Therapeutics (NKTR) revenue was down 43.9% from $98.4M (Dec 31, 2024) to $55.2M (Dec 31, 2025). Statements: https://lician.com/financials/nktr
What is NKTR's market cap?
Nektar Therapeutics (NKTR) market cap is $307.2M on the latest cached fundamentals snapshot.
What kind of company is NKTR?
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Where is NKTR stock news listed?
Cached stock news for Nektar Therapeutics (NKTR) is listed at https://lician.com/news/nktr. Filings: https://lician.com/sec/nktr
Not investment advice.